In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

InSite Vision Inc.

Division of Sun Pharmaceutical Industries Ltd.
www.insitevision.com

Latest From InSite Vision Inc.

Sun Hopes Cequa’s Nano Formulation Makes Big Impact

Sun’s now-approved higher concentration, quicker-acting formulation of cyclosporine A could offer competitive advantage in dry eye versus Allergan’s Restasis, but is it enough to offset lower costs of pending generic cyclosporines?

Approvals Business Strategies

Pfizer Ex-Marketing Director Agrees To Injunction, Ending Trade Secret Suit

Former Pfizer employee has joined Sun Pharma as it launches ophthalmic drug and expands its specialty portfolio, which includes Phase III monoclonal antibody for treatment of psoriasis.

BioPharmaceutical Policy

First US Branded Ophthalmic Launch A ‘Milestone’ For Sun

India’s biggest drug firm Sun has just launched its first branded ophthalmic product in the US, marking what the company calls “a milestone” in its quest to build scale and seek steady revenue streams in the global specialty drug business.

Launches Ophthalmic

M&A Trends: The Growing Indian Appetite

A recent round table on pharma industry trends has highlighted the hunger of cash-rich Indian firms for acquiring companies with niche portfolios in regulated markets including the US. Innovator companies shedding their generic units also present significant opportunities for Indian firms. Both trends are expected to build amid apparent Indian interest in the Teva-Allergan divestiture in Europe.

Commercial Deals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Topical Delivery
  • Therapeutic Areas
  • Inflammation
  • Ophthalmic
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Sun Pharmaceutical Industries Ltd.
  • Senior Management
  • Timothy Ruane, CEO
    Louis Drapeau, VP, CFO
    Lyle M Bowman, PhD, VP, Dev.
  • Contact Info
  • InSite Vision Inc.
    Phone: (510) 865-8800
    965 Atlantic Ave.
    Alameda, CA 94501
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register